市場調查報告書
商品編碼
1287283
精子計數測試市場規模 - 按技術(顯微鏡、色譜免疫分析和量熱反應、基於智慧手機)、按年齡組(34歲及以下、34歲、35-40歲、41歲及以上)、按最終用途及預測,2023 - 2032年Sperm Count Test Market Size - By Technique (Microscopy, Chromatographic Immunoassay & Calorimetric Reaction, Smartphone-based), By Age Group (34 & Below, 34 Years, 35-40 Years, 41 Years & Above), By End-use & Forecast, 2023 - 2032 |
全球精子計數測試市場規模將在2032年之前積累大量收益。一些經濟體的快速工業化促使醫院和其他治療設施的建設,並配備了先進的精子計數測試工具,對行業格局產生了積極影響。此外,行業的成長也可以歸功於全球蓬勃發展的醫療設備部門。舉例來說,根據IBEF的數據,到2025年,印度的醫療設備行業有可能達到500億美元。
整個精子數量測試市場根據技術、年齡組、終端用途和地區分類。
色譜免疫測定和量熱反應部分的精子計數測試市場將在2032年之前顯著擴大。色譜免疫測定法和量熱反應法在精子數量測試中都有很高的準確性和精確度,這有利於它們的採用。這些方法甚至可以檢測出精子濃度、活力和存活率的微小變化,使醫療保健提供者能夠對病人的最佳治療方案做出更明智的決定。
就年齡段而言,從2023年到2032年,34歲年齡段的精子計數測試市場佔有率將以有利可圖的複合年成長率成長。這個年齡段的男性不孕不育症的發病率越來越高,增加了對精子數量測試的需求。此外,這一人群也很容易因過度飲酒和吸煙而出現生活方式紊亂,從而影響到他們的生育能力。該部分的成長也可歸因於這個年齡段的人對生殖健康的認知不斷提高。
根據最終用途,醫院和診所部分的市場價值將在2032年之前明顯成長。醫院和診所有大量具有成本效益的診斷解決方案,增加了這些設施的病人數量。此外,政府對建設新醫院和診所的投資激增,將促進該領域的成長。 2022年10月,美國政府公佈了一項超過1.1億美元的投資,以改善農村人口的醫療保健。這項投資將有助於在農村地區建立醫院和診所。
歐洲精子數量測試行業將在2023-2032年期間見證可觀的成長。該地區男性不孕不育率的成長,增加了對精子數量測試的需求。區域擴張也可歸因於完善的醫療基礎設施和日益成長的生殖健康意識。歐洲也有一個強大的市場領導者,如Vitrolife AB,和其他不斷從事產品創新的公司。這也將有利於估計期內的市場動態。
Global Sperm Count Test Market size will amass substantial gains through 2032. Rapid industrialization across several economies has led to the construction of hospitals and other treatment facilities with advanced sperm count test kits, positively impacting the industry landscape. Moreover, industry growth can also be ascribed to the flourishing medical device sector globally. To illustrate, according to IBEF, the medical device industry in India has the potential to hit USD 50 billion by 2025.
The overall sperm count test market is divided based on technique, age group, end-use, and region.
Sperm count test market from the chromatographic immunoassay & calorimetric reaction segment will expand significantly through 2032. Both chromatographic immunoassay and calorimetric reaction offer high levels of accuracy and precision in sperm count testing, which favors their adoption. These methods can detect even small variations in sperm concentration, motility, and viability, enabling healthcare providers to make more informed decisions about the best course of treatment for their patients.
In terms of age group, sperm count test market share from the 34 years segment will grow at a lucrative CAGR from 2023 to 2032. Growing prevalence of infertility in males of this age has increased the need for sperm count tests. Moreover, this demographic is also susceptible to lifestyle disorders due to excessive alcohol intake and smoking, which affects their fertility. Segment growth can also be attributed to growing awareness about reproductive health among people of this age group.
Based on end use, the market value from the hospitals & clinics segment will grow notably through 2032. High availability of cost-effective diagnostic solutions in hospitals & clinics has increased patient footfall in these facilities. Moreover, surging government investments in building new hospitals & clinics will contribute to segment growth. In October 2022, the U.S. government unveiled an investment of more than USD 110 million to improve healthcare for rural people. This investment will help build hospitals & clinics in rural locations.
Europe sperm count test industry will witness appreciable growth during 2023-2032. Growing incidence of male infertility rates in the region has increased the demand for sperm count tests. Regional expansion can also be attributed to well-established healthcare infrastructure and the growing awareness about reproductive health. Europe also has a robust presence of market leaders such as Vitrolife AB, and others constantly engaged in product innovations. This will also favor the market dynamics over the estimation period.